Recent Company News

• 06:05 AM ET Aug 18, 2025
  

  Natera announces positive topline results from Phase III IMvigor011 clinical trial ($163.02, 0.00)

• 11:54 PM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:00 PM ET Jul 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 03:11 AM ET Jul 24, 2025
  

  Chugai Pharmaceutical reports H1 core net income attributable ¥94.3B, (17%) vs year-ago ¥113.5B (¥7238.0000, 0)

• 02:16 AM ET Jul 24, 2025
  

  Roche reports H1 results; StreetAccount notes the H1 report includes financial performance metrics for Chugai Pharmaceutical (¥7258.0000, +141)

• 09:03 AM ET Jul 22, 2025
  

  Roche Canada announces Polivy for First-Line Treatment of Adults With Large B-Cell Lymphoma is now Publicly Reimbursed in Québec (CHF 253.40, -2.20)

• 08:17 PM ET Jul 21, 2025
  

  Sarepta Therapeutics to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the U.S., effective 22-Jul ($13.32, 0.00)

• 03:05 AM ET Jul 07, 2025
  

  Chugai Pharmaceutical, Singapore Gero PTE enter joint research and license agreement to develop novel therapies for age-related diseases (¥7140.0000, 0)

• 08:21 PM ET Jul 01, 2025
  

  NICE recommends Chugai Pharmaceutical's Nemluvio to treat moderate to severe atopic dermatitis in people 12 years and over (¥7064.0000, -173)